Vevye Ophthalmic Solution Trial for Meibomian Gland Dysfunction Underway
A clinical trial is evaluating the efficacy of Vevye® (cyclosporine 0.1%) in treating meibomian gland dysfunction over a 24-week period.
Asset / Drug
Drug and asset intelligence for Vevye with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.